Statins for aortic stenosis? Still waiting for answers: Commentary

Nature Clinical Practice Cardiovascular Medicine

Volumn 4, Issue 7, 2007, Pages 358-359

  Otto, Catherine M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD40 ANTIGEN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ANGIOGENESIS; AORTA VALVE REPLACEMENT; AORTA VALVE STENOSIS; ATHEROSCLEROSIS; CALCIFICATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; ECHOCARDIOGRAPHY; ENDOTHELIUM LESION; FOLLOW UP; HEART HEMODYNAMICS; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPID STORAGE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SHORT SURVEY; SUDDEN DEATH; SYMPTOMATOLOGY; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 34347387518     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio0907     Document Type: Short Survey

References (5)

1. Freeman RV and Otto CM (2005) Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 111: 3316-3326
2. O'Brien KD (2006) Pathogenesis of calcific aortic valve disease: A disease process comes of age (and a good deal more). Arterioscler Thromb Vasc Biol 26: 1721-1728
3. Rosenhek R et al. (2004) Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 110: 1291-1295
4. Cowell SJ et al. for the Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators (2005) A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 352: 2389-2397
5. Newby DE et al. (2006) Emerging medical treatments for aortic stenosis: Statins, angiotensin converting enzyme inhibitors, or both? Heart 92: 729-734